Tobira Therapeutics Inc. (NASDAQ:TBRA) shares shot up 3.5% during mid-day trading on Friday . The company traded as high as $11.67 and last traded at $11.34, with a volume of 64,163 shares changing hands. The stock had previously closed at $10.96.

A number of brokerages have recently weighed in on TBRA. Cantor Fitzgerald began coverage on shares of Tobira Therapeutics in a research note on Wednesday, July 6th. They set a “buy” rating and a $27.00 price objective for the company. Zacks Investment Research cut shares of Tobira Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 10th. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Tobira Therapeutics in a research note on Tuesday, May 10th. Finally, Leerink Swann reissued a “buy” rating on shares of Tobira Therapeutics in a research note on Monday, May 2nd. Five research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $20.20.

The stock’s market cap is $211.67 million. The stock has a 50 day moving average price of $11.68 and a 200 day moving average price of $8.79.

Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. Equities research analysts forecast that Tobira Therapeutics Inc. will post ($2.49) EPS for the current year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $13.04, for a total transaction of $871,254.56. Following the completion of the transaction, the insider now directly owns 2,073,022 shares of the company’s stock, valued at approximately $27,032,206.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP purchased a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics as of its most recent SEC filing.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.